Keppra 100 mg/ml oral solution

  • Name:

    Keppra 100 mg/ml oral solution

  • Company:
    info
  • Active Ingredients:

    Levetiracetam

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 18/02/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 18/2/2020

Click on this link to Download PDF directly

UCB (Pharma) Ireland Limited

UCB (Pharma) Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Briviact 10 mg/ml solution for injection/infusion Active Ingredients Brivaracetam
Medicine Name Briviact 10mg/ml oral solution Active Ingredients Brivaracetam
Medicine Name Briviact film-coated tablets Active Ingredients Brivaracetam
Medicine Name Cimzia 200 mg solution for injection in pre-filled pen Active Ingredients Certolizumab Pegol
Medicine Name Cimzia 200 mg solution for injection in pre-filled syringe Active Ingredients Certolizumab Pegol
Medicine Name EVENITY 105 mg solution for injection in pre-filled pen Active Ingredients Romosozumab
Medicine Name Keppra 100 mg/ml oral solution Active Ingredients Levetiracetam
Medicine Name Keppra 1000 mg film-coated tablets Active Ingredients Levetiracetam
Medicine Name Keppra 100mg/ml concentrate for solution for infusion Active Ingredients Levetiracetam
Medicine Name Keppra 250 mg film-coated tablets Active Ingredients Levetiracetam
Medicine Name Keppra 500 mg film-coated tablets Active Ingredients Levetiracetam
Medicine Name Keppra 750 mg film-coated tablets Active Ingredients Levetiracetam
Medicine Name Neupro 1mg/24hr and 3 mg/24 hTransdermal Patch Active Ingredients Rotigotine
Medicine Name Neupro 2mg/24hr Transdermal Patch Active Ingredients Rotigotine
Medicine Name Neupro 4 mg/24hr, 6 mg/24hr, 8 mg/24hr Transdermal Patch Active Ingredients Rotigotine
Medicine Name Tylex 30mg/500mg Hard Capsules Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Vimpat 10 mg/ml solution for infusion Active Ingredients lacosamide
Medicine Name Vimpat 10 mg/ml syrup Active Ingredients lacosamide
Medicine Name Vimpat 50 mg, 100 mg, 150 mg, 200 mg film-coated tablets Active Ingredients lacosamide
Medicine Name Xyrem 500mg/ml oral solution Active Ingredients Sodium oxybate
Medicine Name Xyzal 0.5mg/ml oral solution Active Ingredients Levocetirizine dihydrochloride
Medicine Name Xyzal 5mg Tablets Active Ingredients Levocetirizine dihydrochloride
Medicine Name Xyzal 5mg/ml Oral Drops, Solution Active Ingredients Levocetirizine dihydrochloride
Medicine Name Zirtek Allergy Relief 10 mg film-coated tablets (OTC) Active Ingredients Cetirizine Dihydrochloride
Medicine Name Zirtek Oral Solution Active Ingredients Cetirizine Dihydrochloride
1 - 0 of 27 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 February 2020 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 4 - How to Report a Side Effect

Addition of "HPRA Pharmacovigilance Website: www.hpra.ie"

Section 6 - Manufacturer

Addition of "Or UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium"

Section 6 - Date of Revision

Addition of "January 2020"

Updated on 18 February 2020 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to Section 4.8 - Undesireable Effects (reporting of suspected adverse reactions)

Addition of "HPRA Pharmacovigilance Website: www.hpra.ie"

Change to Section 10 - Date of revision of text

Addition of "January 2020"

Updated on 18 October 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4 of the SPC the following has been added:

 

Abnormal and aggressive behaviours

Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviours are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section 4.2.

 

Updated on 18 October 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

In section 4 of the leaflet the following has been added:

 

Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:

  • Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.

 

 

Updated on 1 April 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 29 March 2019 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 13 March 2019 PIL

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects

Updated on 13 March 2019 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Pregnancy wording update, dysgeusia, pregnancy malformation update and gait disturbance

Updated on 2 January 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 2 January 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to section 4.4: addition of warnings regarding Acute Kidney injury and blood cell counts


Change to section 4.8: addtion of Acute Kidney injury and blood cell counts as adverse reactions within the tabulated list of advers reacions

Change to section 10: date of revision

Updated on 23 December 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 23 December 2016 PIL

Reasons for updating

  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 8 September 2015 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Oral Solution

Throughout:
Replacement of Keppra with Levetiracetam.

4.2 Posology and method of administration
Addition of details for instruction on discontinuation.
Additional details for use of the oral solution for doses under 250mg.

4.4 Special warnings and precautions for use
Removal of details for instruction on discontinuation.
Removal of statement for lack of safety and efficacy information for use in infants.

4.5 Interaction with other medicinal products and other forms of interaction
Addition of details of interaction with Methotrexate.
Removal of statement relating to excretion by active tubular secretion.
Removal of statement that no data exists for interaction with antacids.

4.6 Fertility, pregnancy and lactation
Removal of “As with other antiepileptic medicinal products” clause from pregnancy warning

4.7 Effects on ability to drive and use machines
Driving warning upgraded to ‘minor or moderate influence…”

4.8 Undesirable effects
Editorial change to re-arrange the order of the opening paragraph.
Addition of the statement: “Adverse reactions are presented in the order of decreasing seriousness and their…”
Addition of:
• Hypersensitivity
Reordering of statement for coadminitration with topiramate.
Addition of post approval study data for infants.

5.1 Pharmacodynamic properties
Mechanism of action updated.
Infant data added.

5.3 Preclinical safety data
Fetal updated to foetal
Removal of Environmental Risk Assessment (ERA).

6.1 List of excipients
Opadry reference removed

10. DATE OF REVISION OF THE TEXT
Date of revision updated

Updated on 7 September 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to further information section
  • Change to date of revision
  • Change to dosage and administration

Updated on 24 March 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 28 January 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

To add 'hyponatremia' as new ADR 

Updated on 9 January 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 20 December 2013 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.8     Undesirable effects

Immune system disorders

Rare: Drug reaction with eosinophilia and systemic symptoms (DRESS)

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via IMB and MHRA websites (refer to SmPC)

Updated on 4 September 2013 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.5     Interaction with other medicinal products and other forms of interaction

Laxatives

There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.

 

 

4.6     Fertility, pregnancy and lactation

Pregnancy

Postmarketing data from several prospective pregnancy registries have documented outcomes in over 1000 women exposed to levetiracetam monotherapy during the first trimester of pregnancy. Overall, these data do not suggest a substantial increase in the risk for major congenital malformations, although a teratogenic risk cannot be completely excluded. Therapy with multiple antiepileptic medicinal products is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be considered. Studies in animals have shown reproductive toxicity (see section 5.3).

Keppra is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.

 

4.8     Undesirable effects

Blood and lymphatic system disorders

Rare: agranulocytosis

Updated on 19 September 2012 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

New SPC for individual product

Updated on 23 August 2012 PIL

Reasons for updating

  • Change to side-effects

Updated on 16 December 2011 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 28 November 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 19 October 2011 PIL

Reasons for updating

  • Change to side-effects
  • Change to dosage and administration

Updated on 13 May 2011 PIL

Reasons for updating

  • Change to further information section
  • Change to MA holder contact details

Updated on 29 October 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 16 September 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 6 April 2010 PIL

Reasons for updating

  • Change to dosage and administration
  • Introduction of new pack/pack size

Updated on 10 March 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 21 June 2008 PIL

Reasons for updating

  • Change of manufacturer

Updated on 28 November 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 9 August 2007 PIL

Reasons for updating

  • Change of manufacturer

Updated on 6 February 2007 PIL

Reasons for updating

  • Change to, or new use for medicine

Updated on 14 July 2006 PIL

Reasons for updating

  • Change to, or new use for medicine

Updated on 19 July 2005 PIL

Reasons for updating

  • Change to further information section

Updated on 19 January 2005 PIL

Reasons for updating

  • New PIL for new product